Q2 2026 BIO-Key International Inc Earnings Call Transcript
Key Points
- Q2 2026 net loss improved 51% year-over-year, with gross margin expanding to 87% from 73%.
- License fee revenue surged 53% in Q2, driving overall revenue growth of 13% and 23% for the first half.
- Strong momentum in EMEA with new partnerships (e.g., Mitabi Tech in Saudi Arabia) and national-scale projects like the Central Bank of Jordan.
- Recent warrant transaction raised $2.5 million, boosting cash to over $4.5 million and strengthening the balance sheet.
- Regained NASDAQ compliance after reverse stock split, providing a stable listing platform.
- Growing pipeline in AI governance and agentic AI, positioning biometrics as a key solution for human oversight.
- Cost containment efforts reduced operating expenses by 5% in Q2, supporting path to profitability.
- Q2 results missed expectations due to a delayed hardware order, pushing revenue to the second half.
- Hardware revenue declined 19% in Q2, reflecting timing issues and the absence of a large deployment.
- Service, maintenance, and other revenue fell 28% due to lower non-recurring service revenue and renewal timing.
- The company still reported a net loss of $577,000 in Q2, though improved from prior year.
- Stock price has been under pressure, partly due to warrant exercises and market volatility, despite positive news.
- Dependence on a few large orders for second-half profitability creates execution risk.
- Potential dilution from new warrants (1.2 million shares) could impact shareholders, though capped at 9.9% ownership.
Good morning, everyone.
Thank you for standing by and welcome to BioKey International's second quarter 2026 conference call.
During management's prepared remarks, all participants will be in listen-only mode.
Afterwards, listeners will be invited to participate in a question-and-answer session. As a reminder, this conference is being recorded today, Friday, August 14th, 2026. I will now turn the call over to Bill Jones of Investor Relations. Please go ahead.
Thank you, Chloe.
Hosting today are BioKeys Chairman and CEO, Mike DiPasquale and its CFO, C.C. Welch.
As a reminder, today's call and webcast as well as answers to investor questions include forward-looking statements.
These are subject to risks and uncertainties that may cause actual results to differ materially from current expectations. Words such as anticipate, believe, expect, plan or project and similar words identify and express forward-looking statements.
These statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
